Description
Specifications
| Form | Lyophilized powder, single vial |
| Total | 30 mg (BPC-157, TB-500 and Cartalax) |
| Made in | USA |
| Testing | Third-party identity and purity, every lot |
| BPC-157 | C₆₂H₉₈N₁₆O₂₂ · MW 1419.5 · CAS 137525-51-0 |
| TB-500 | C₂₁₂H₃₅₀N₅₆O₇₈S · MW 4963.4 · CAS 77591-33-4 |
| Cartalax | Ala-Glu-Asp tripeptide bioregulator |
How Is This Blend Studied?
This blend combines three peptides researched for connective tissue remodeling. BPC-157 is studied for cytoprotective and angiogenic signaling, TB-500 for actin binding and cell migration, and Cartalax, a short bioregulator peptide, for gene-expression effects in cartilage cell models.
Storage
Store the sealed vial at −20 °C long-term or 2–8 °C short-term, away from light. Once reconstituted in the lab, keep at 2–8 °C and avoid repeated freeze-thaw cycles. See our storage guide.
FAQ
How is this different from the BPC-157 / TB-500 blend?
The BPC-157 / TB-500 blend contains the same two peptides without Cartalax.
Is a Certificate of Analysis available?
Yes. Tap “View Certificate of Analysis” on this page for the current lot’s third-party COA.
Do you provide use or dosing guidance?
No. This product is sold strictly for laboratory research, and orders indicating human or animal use are cancelled.
For laboratory research use only. Not for human consumption.
